A Clinical Trial Evaluating the Safety and Efficacy of IDP-110 in Patients With Acne Vulgaris
Phase 3
Completed
- Conditions
- Acne Vulgaris
- Interventions
- Registration Number
- NCT00663286
- Lead Sponsor
- Dow Pharmaceutical Sciences
- Brief Summary
The purpose of this study is to assess the effectiveness of IDP-110 in treating patients with acne vulgaris.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1399
Inclusion Criteria
- Presence of inflammatory and non-inflammatory lesions
Exclusion Criteria
- Dermatological conditions of the face other than acne that could interfere with clinical evaluations
- Female subjects who are pregnant, nursing, planning a pregnancy, or become pregnant during the study
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 1 IDP-110 - 4 Vehicle - 3 Benzoyl peroxide - 2 Clindamycin -
- Primary Outcome Measures
Name Time Method Change from baseline in number of lesions 12 weeks
- Secondary Outcome Measures
Name Time Method Change from baseline in global severity 12 weeks
Trial Locations
- Locations (32)
Burke Pharmaceutical Research
🇺🇸Hot Springs, Arkansas, United States
The Savin Center, PC
🇺🇸New Haven, Connecticut, United States
Webster Dermatology, PA
🇺🇸Hockessin, Delaware, United States
Skin Care Research, Inc.
🇺🇸Boca Raton, Florida, United States
Advanced Dermatology and Cosmetic Surgery
🇺🇸Ormond Beach, Florida, United States
North Florida Dermatology Associates, PA
🇺🇸Jacksonville, Florida, United States
Dermatology Research
🇺🇸Pinellas Park, Florida, United States
Florida Dermatology Institute
🇺🇸West Palm Beach, Florida, United States
Derm Center of Augusta
🇺🇸Augusta, Georgia, United States
MedaPhase Inc.
🇺🇸Newnan, Georgia, United States
Scroll for more (22 remaining)Burke Pharmaceutical Research🇺🇸Hot Springs, Arkansas, United States